#GLP1 #Menopause #Tirzepatide #Semaglutide #WeightLoss
Not losing weight on a GLP-1 after menopause? You’re not imagining it, but your body isn’t broken and the medication hasn’t stopped working. In this video, I’m Dr. Mohammed Paika, board-certified in internal medicine and obesity medicine. I break down what the research really shows about GLP-1s like tirzepatide (Mounjaro, Zepbound) and semaglutide (Ozempic, Wegovy) after menopause.
You’ll learn what menopause does to fat, muscle and metabolism, and how much weight women actually lose at each stage of menopause in the clinical trials. I’ll show you why real-world results can lag, what the newest hormone therapy studies show and why they don’t prove cause and effect, and how to protect your muscle and bones. I’ll also walk you through the 5-step plan I use with my midlife patients.
📩 FREE GLP-1 Diet Cookbook + Weekly Newsletter
https://www.drmohammedpaika.com/newsletter
🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime Access
Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.
https://www.drmohammedpaika.com
TIMESTAMPS
0:00 Why weight loss feels harder after menopause
1:56 What menopause does to your body
4:15 Do GLP-1s still work after menopause?
7:12 Why it feels harder in real life
9:06 Hormone therapy and GLP-1s: what the data shows
11:21 Free GLP-1 Diet Cookbook
11:44 Protecting your muscle and bones
13:42 GLP-1 Masterclass
14:12 The 5-step midlife GLP-1 plan
15:35 A real viewer example
16:41 Final thoughts
📚 REFERENCES
Greendale GA, et al. Changes in body composition and weight during the menopause transition (SWAN). JCI Insight. 2019;4(5):e124865.
Lovejoy JC, et al. Increased visceral fat and decreased energy expenditure during the menopausal transition. Int J Obes. 2008;32(6):949-958.
Pontzer H, et al. Daily energy expenditure through the human life course. Science. 2021;373(6556):808-812.
Karppinen JE, et al. Age but not menopausal status is linked to lower resting energy expenditure. J Clin Endocrinol Metab. 2023;108(11):2789-2797.
Thomson ZO, et al. Weight loss outcomes in premenopausal versus postmenopausal women during behavioral weight loss interventions. Menopause. 2021;28(3):337-346.
Tchang BG, et al. Body weight reduction in women treated with tirzepatide by reproductive stage (SURMOUNT post hoc). Obesity. 2025;33:851-860.
García-Pérez LE, et al. Tirzepatide weight reduction by sex: SURMOUNT-1 to -4 post hoc. Presented at EASD 2024.
Castaneda R, et al. Sex, not age, predicts weight loss outcomes with tirzepatide. Obesity. 2026;34(Suppl 2):132-145.
Huvinen E, et al. Body weight loss with semaglutide 7.2 mg is independent of menopausal status (STEP UP post hoc). Presented at the European Congress on Obesity, 2026.
Castaneda R, et al. Impact of reproductive stage and menopausal hormone therapy on weight loss outcomes with tirzepatide. Presented at The Menopause Society Annual Meeting, 2025.
Nedeltcheva AV, et al. Insufficient sleep undermines dietary efforts to reduce adiposity. Ann Intern Med. 2010;153(7):435-441.
Hurtado MD, et al. Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use. Menopause. 2024;31:266.
Castaneda R, et al. Menopause hormone therapy and tirzepatide-associated weight loss in postmenopausal women. Lancet Obstet Gynaecol Womens Health. 2026;2(2):e118-e128.
Hurtado MD, et al. Semaglutide reduces body weight regardless of menopause status (STEP and OASIS 4 post hoc). Presented at ObesityWeek, 2025.
Papadakis GE, et al. Menopausal hormone therapy is associated with reduced total and visceral adiposity (OsteoLaus). J Clin Endocrinol Metab. 2018;103(5):1948-1957.
Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002.
Look M, et al. Body composition changes during weight reduction with tirzepatide in SURMOUNT-1. Diabetes Obes Metab. 2025.
Jensen SBK, et al. Bone health after exercise alone, GLP-1 receptor agonist treatment, or combination treatment. JAMA Netw Open. 2024;7(6):e2416775.
Watson SL, et al. High-intensity resistance and impact training in postmenopausal women with low bone mass (LIFTMOR). J Bone Miner Res. 2018;33(2):211-220.
⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.
